

Page 10, line 13, delete "Sepharose" and insert therefor --SEPHAROSE resins--.

Page 11, line 17, delete "Sepharose" and insert therefor --SEPHAROSE resins--.

Page 11, line 24, delete "Sepharose" and insert therefor --SEPHAROSE--.

Page 11, line 27, delete "Sepharose" and insert therefor --SEPHAROSE resins--.

Page 12, line 34, delete "Sephadex®" and insert therefor "SEPHADEX--.

Page 13, line 12, delete "Sephadex®" and insert therefor "SEPHADEX--.

Page 13, line 19, delete "Sephadex®" and insert therefor --SEPHADEX--.

Page 14, line 14, delete "Sepharose" and insert therefor --SEPHAROSE resins--.

Page 14, line 21, delete "peptide-Sepharose" and insert therefor --peptide-
SEPHAROSE resins--.

Page 14, line 27, delete "peptide-Sepharose" and insert therefor --peptide-
SEPHAROSE resins--.

Page 16, line 12, delete "Sepharose" and insert therefor --SEPHAROSE resins--.

IN THE ABSTRACT

At line 15, please delete "said".

IN THE CLAIMS

Please cancel claim 1 without prejudice or disclaimer thereof.

Please amend the following claims:

5. [The use of EPO peptides as claimed in claim 1] A method of using erythropoietin (EPO) peptide for the preparation of epitope-specific anti-EPO antibodies, an epitope being defined as being composed of one or more peptides, or one or more sections of peptide sequences, wherein said EPO peptide consists essentially of a peptide of less than the complete erythropoietin protein, said peptide selected from the group consisting of amino-acid positions 1 to 35 (P4), 7 to 22 (P4/1), 44 to 78 (P3), 52 to 63 (P3/1), 74 to 109 (P1), 84 to 95 (P1/1), 93 to 137 (P5), 110 to 123 (P5/1), 142 to 166 (P2) and 152 to 166 (P2/1) in accordance with the numbering of the amino-acid positions of natural EPO, and/or directed against an EPO epitope [according to claim 5], an epitope being defined as being composed of one or more peptides, or one or more sections of peptide sequences.

6. An [epitope-specific anti-EPO] antibody[, which is directed against an EPO peptide as claimed in claim 1, and/or directed against an EPO epitope according to claim 5] directed against an erythropoietin (EPO) peptide, wherein said antibody neutralizes the biological activity of EPO, and wherein said EPO peptide consists essentially of a peptide of less than the complete erythropoietin protein, said peptide having an amino acid sequence selected from the group consisting of amino-acid positions 138 to 166 (P2) and 152 to 166 (P2/1) in accordance with the numbering of the amino-acid positions of natural EPO.

LAW OFFICES

INNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

7. The [epitope-specific anti-EPO] antibody [as claimed in] of claim 6[, which]
in which the antibody is a monoclonal antibody.

12. A diagnostic aid containing an EPO peptide as [claimed] defined in claim
[1] 5 for the detection of anti-EPO antibodies.

14. A pharmaceutical composition containing an epitope-specific anti-EPO
antibody as claimed in claim 8 and[, where appropriate, pharmaceutically tolerated
auxiliaries and additives] a pharmaceutically acceptable excipient.

15. A pharmaceutical composition containing an anti-idiotype antibody as
claimed in claim 9 and[, where appropriate, pharmaceutically tolerated auxiliaries and
additives] a pharmaceutically acceptable excipient.

Please add the following new claims:

--17. An anti-erythropoietin (EPO) antibody directed against epitopes that binds
to the EPO receptor.

18. An anti-EPO antibody as claimed in claim 17, which neutralizes the
biological activity of EPO.

19. An anti-EPO antibody as claimed in claim 17, which is a monoclonal
antibody.

20. A diagnostic aid containing one or more anti-EPO antibodies as claimed in
claim 17 for the detection of EPO.

LAW OFFICES

INNECAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000